Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Penumbra, Inc. (PEN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that together outline Penumbra’s financial condition, major corporate events and obligations as a NYSE-listed issuer.
Among the most significant recent filings is a Form 8-K dated January 15, 2026, in which Penumbra reports entry into an Agreement and Plan of Merger with Boston Scientific Corporation and a Boston Scientific subsidiary. The filing describes the structure of the merger consideration, the mix of cash and Boston Scientific common stock, and the conditions required for closing. It also states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time.
Other Form 8-K filings highlighted here include results of operations and financial condition for specific quarters, where Penumbra furnishes earnings press releases as exhibits. These filings discuss revenue growth, gross margin, operating margin and the use of non-GAAP measures such as constant currency revenue, non-GAAP income from operations and adjusted EBITDA. The company explains how these non-GAAP metrics are calculated and why management considers them useful for assessing underlying business performance.
Additional 8-Ks address corporate governance and leadership changes, such as the appointment of a new company president and related compensation arrangements. These filings provide detail on board and executive decisions, equity awards and related person transactions, all within the framework of SEC disclosure requirements.
Through this page, users can follow Penumbra’s formal reporting on material events, financial results and the proposed merger with Boston Scientific. Stock Titan’s platform associates each filing with AI-powered summaries designed to explain the core points of lengthy documents, helping readers quickly understand items such as merger terms, earnings highlights, and key governance changes without having to parse every line of the underlying text.
For deeper research, investors can review the full text of Penumbra’s 10-K and 10-Q reports via the SEC’s EDGAR system, while using the summaries and context on this page as a guide to the most important disclosures affecting PEN and its anticipated transition to a wholly owned subsidiary of Boston Scientific.
Penumbra Inc. executive Johanna Roberts, EVP, General Counsel & Secretary, reported a tax-related share withholding tied to equity compensation. On 12/15/2025, 1,130 shares of Penumbra common stock were disposed of at $309.15 per share under transaction code F, which indicates shares withheld to satisfy tax obligations on vesting restricted stock units.
After this transaction, she beneficially owns 62,706 shares of Penumbra common stock, and a portion of these shares remains subject to vesting. No derivative securities transactions were reported.
Penumbra Inc. director Arani Bose reported multiple open-market sales of Penumbra common stock on 12/11/2025, carried out under a pre-arranged Rule 10b5-1 trading plan. The transactions, all coded as sales, were executed in several tranches, including 2,030 shares at a weighted average price of $305.19, 4,946 shares at $306.6, and 3,523 shares at $311.47, with other trades priced in the general range of $305–$312 per share.
Following one of the reported transactions, the filing shows 258,462 shares of Penumbra common stock beneficially owned indirectly through Bose Family Holdings II, LLC, and a portion of these shares is subject to vesting. The filing emphasizes that several trades were executed in multiple lots within stated price ranges, with the weighted average prices reported and full trade details available upon request.
Penumbra Inc. executive vice president, general counsel and secretary reported a small stock sale under a pre-arranged trading plan. On
Penumbra, Inc. reported insider trading activity by its EVP, General Counsel & Secretary, Johanna Roberts. On 12/01/2025, she executed several small open-market sales of Penumbra common stock under a pre-arranged Rule 10b5-1 trading plan. The reported weighted average sale prices ranged from about $292.09 to $298.02 per share across multiple trades. After these transactions, she beneficially owned 64,136 shares of Penumbra common stock, and a portion of these shares is subject to vesting. All sales were reported as directly owned shares.
Penumbra, Inc. director reports small stock sale under 10b5-1 plan
A Penumbra Inc (ticker PEN) director reported selling 100 shares of common stock on 12/02/2025 at a price of $292.98 per share. After this transaction, the reporting person beneficially owns 8,416 shares of Penumbra common stock. The filing notes that the sale was executed under the director’s pre-established Rule 10b5-1 trading plan, which is designed to permit scheduled trades. The company also discloses that a portion of the remaining shares is still subject to vesting conditions.
Penumbra insider Harpreet Grewal has filed a notice to sell company stock under Rule 144. The notice covers 100 shares of Penumbra common stock to be sold through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 12/02/2025. The stock was originally acquired on 03/26/2006 in a private purchase from Penumbra for cash.
The filing also lists recent sales by the same seller over the prior three months: 186 shares of common stock on 09/02/2025 for gross proceeds of 50,627.34, another 186 shares on 10/02/2025 for 46,241.46, and 186 shares on 11/04/2025 for 42,329.88. Penumbra had 38,999,129 shares of common stock outstanding at the time indicated, which provides context for the scale of these transactions.
Penumbra Inc. executive reports small stock sale under trading plan
Penumbra Inc.'s EVP, General Counsel & Secretary, Johanna Roberts, reported selling 1,800 shares of the company's common stock on 11/25/2025. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to trade shares according to a set schedule. The weighted average sale price was $300.06 per share, with individual trades executed between $300.00 and $300.54.
After this transaction, Roberts beneficially owns 64,736 shares of Penumbra common stock, and a portion of these shares remains subject to vesting, meaning they will be earned over time based on continued service or other conditions.
Penumbra Inc. (PEN) director Arani Bose reported recent changes in his holdings of the company’s common stock. On 11/25/2025, an affiliate entity, Bose Family Holdings II, LLC, sold 7,500 shares of Penumbra common stock at a weighted average price of $300.19 per share, executed under a pre-arranged Rule 10b5-1 trading plan. On 11/26/2025, the reporting person made a bona fide gift of 1,799 shares with no payment in consideration. Following these transactions, the filing shows 273,462 shares of Penumbra common stock held indirectly through Bose Family Holdings II, LLC and an additional 558 shares, a portion of which is subject to vesting.
Penumbra Inc. (PEN) director Arani Bose reported share sales in the company’s stock. On 11/21/2025, an indirect ownership vehicle sold 7,338 shares of Penumbra common stock at a weighted average price of $290.55, followed by a sale of 162 shares at a weighted average price of $291.09. The sales were made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a preset schedule.
After these transactions, the reporting person beneficially owned 282,761 shares of Penumbra common stock indirectly through Bose Family Holdings II, LLC. A portion of the reported shares is subject to vesting, meaning some shares may become fully owned over time based on conditions such as continued service or performance.
Penumbra, Inc. (PEN) insider sale notice: A holder intends to sell 2,100 shares of Penumbra common stock on the NYSE through J.P. Morgan Securities LLC. The notice lists 39,162,197 common shares outstanding and an approximate sale date of 11/25/2025.
The 2,100 shares were acquired from the issuer on 12/28/2022 through an option exercise paid in cash. Over the past three months, the same seller has completed three separate sales of 600 Penumbra common shares each, on 09/02/2025, 10/01/2025, and 11/10/2025, with disclosed gross proceeds for each transaction.
By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Penumbra’s current or prospective operations.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
